Hematology, Ankara Numune Training and Research Hospital, Ankara, Turkey.
Biochemistry, Saglik Bakanligi Ankara Egitim ve Arastirma Hastanesi, Ankara, Turkey.
Int J Lab Hematol. 2018 Dec;40(6):721-725. doi: 10.1111/ijlh.12910. Epub 2018 Aug 20.
Although tests of global hemostasis prothrombin time (PT) and activated partial thromboplastin time (aPTT) should not be used for prediction of bleeding risk, these tests are often used by many clinicians in daily practice particularly as a preoperative screening test. Robust biological variation (BV) data are needed for safe clinical applications of these tests. In this study, a stringent protocol was followed to estimate the BV's for PT, aPTT, and fibrinogen levels.
Weekly blood samples were obtained from 28 healthy individuals (18 females, 10 males) during 10 weeks study period. All measurements were performed with Stago STA-R coagulation analyzer. Prior to coefficient of variation (CV)-analysis of variance (ANOVA), the data were assessed for normality, trends, outliers, and variance homogeneity. Sex-stratified within-individual (CV ) and between-individual (CV ) BV estimates were determined for PT, aPTT, and fibrinogen tests.
No difference was found between male and female estimates of BV. The observed CV and CV estimates were found to be lower than those previously published. Only for fibrinogen, CV was higher than CV .
Following a meticulous protocol, our study results provide up-to-date and more stringent BV estimates of global hemostasis tests.
尽管凝血酶原时间（PT）和活化部分凝血活酶时间（aPTT）等检测全球止血功能的指标不应用于预测出血风险，但这些检测在日常临床实践中常被许多临床医生使用，尤其是作为术前筛查检测。这些检测的安全临床应用需要有可靠的生物学变异（BV）数据。在这项研究中，我们遵循严格的方案来估算 PT、aPTT 和纤维蛋白原水平的 BV。
在 10 周的研究期间，每周从 28 名健康个体（18 名女性，10 名男性）中采集血样。所有测量均使用 Stago STA-R 凝血分析仪进行。在进行变异系数（CV）-方差分析（ANOVA）之前，对数据进行正态性、趋势、离群值和方差同质性评估。针对 PT、aPTT 和纤维蛋白原检测，确定了个体内（CV）和个体间（CV）BV 的性别分层估计值。
BV 的个体内和个体间估计值在男性和女性之间没有差异。观察到的 CV 和 CV 估计值低于先前发表的估计值。只有纤维蛋白原的 CV 高于 CV。
按照严格的方案，我们的研究结果提供了更及时和更严格的全球止血功能检测的 BV 估计值。
